Compounds > phosphatidylcholines
Page last updated: 2024-09-05

phosphatidylcholines and papaverine

phosphatidylcholines has been researched along with papaverine in 6 studies

Compound Research Comparison

Studies
(phosphatidylcholines)		Trials
(phosphatidylcholines)		Recent Studies (post-2010)
(phosphatidylcholines)		Studies
(papaverine)		Trials
(papaverine)		Recent Studies (post-2010) (papaverine)
32,2044435,5936,027305355

Protein Interaction Comparison

ProteinTaxonomyphosphatidylcholines (IC50)papaverine (IC50)
Chain A, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10ARattus norvegicus (Norway rat)0.076
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)2.3
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)8.8
3',5'-cyclic-AMP phosphodiesterase Sus scrofa (pig)1.7
Bile salt export pumpHomo sapiens (human)10
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)1.6
Cytochrome P450 2C19Homo sapiens (human)0.762
Serine hydroxymethyltransferase, mitochondrialHomo sapiens (human)2.6915
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)9
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)9
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)1.4
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)7.2444
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)1.03
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)9
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)0.697
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Rattus norvegicus (Norway rat)0.036
Phosphodiesterase Sus scrofa (pig)0.62
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)0.07

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19902 (33.33)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Falk, M; Fürst, W1
Kubota, K; Taga, F; Takagi, K; Takayanagi, I1
Arnaboldi, R; Benzi, G; Ghigini, B; Gorini, A; Villa, R1
Kajiyama, G; Miura, H; Tazuma, S; Yamashita, G1
Blancas-Mejia, LM; Burciu, C; Franco, DA; Guzman-Villanueva, D; Hari, P; Karamanova, N; Lindsay, S; Migrino, RQ; Ramirez-Alvarado, M; Senapati, S; Truran, S; Weissig, V1
Burciu, C; Franco, DA; Guzman-Villanueva, D; Hari, P; Karamanova, N; Migrino, RQ; Nedelkov, D; Senapati, S; Truran, S; Weissig, V1

Other Studies

6 other study(ies) available for phosphatidylcholines and papaverine

ArticleYear
[Drug permeation through synthetic lipid membranes. Permeability of lecithin-collodium membranes for drugs and metabolites].
    Die Pharmazie, 1974, Volume: 29, Issue:9

    Topics: Buffers; Caffeine; Diffusion; Hexobarbital; Hydrogen-Ion Concentration; Kinetics; Membranes, Artificial; Models, Chemical; Papaverine; Phenobarbital; Phenytoin; Phosphatidylcholines; Quinine; Salicylates; Solutions; Time Factors

1974
Effect of calcium ions and phospholipids on antiacetylcholine action of acetone and papaverine.
    Japanese journal of pharmacology, 1970, Volume: 20, Issue:3

    Topics: Acetone; Acetylcholine; Animals; Calcium; Cell Membrane; Guinea Pigs; Ileum; In Vitro Techniques; Intestine, Small; Muscle, Smooth; Papaverine; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Potassium Chloride; Rabbits; Tissue Extracts

1970
Effect of intermittent mild hypoxia and drug treatment on synaptosomal nonmitochondrial ATPase activities.
    Journal of neuroscience research, 1993, Apr-15, Volume: 34, Issue:6

    Topics: Adenosine Triphosphatases; Animals; Cerebral Cortex; Energy Metabolism; Hypoxia; In Vitro Techniques; Lipid Metabolism; Male; Morpholines; Nicardipine; Oxygen Consumption; Papaverine; Phosphatidylcholines; Rats; Rats, Wistar; Synaptic Membranes; Synaptosomes; Thiophenes

1993
Extracellular and intracellular regulation of biliary lecithin hydrophobicity.
    Digestive diseases and sciences, 1998, Volume: 43, Issue:1

    Topics: Animals; Bile; Cholesterol; Fatty Acids; Hyperbilirubinemia; Papaverine; Phosphatidylcholines; Phospholipids; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Sulfobromophthalein

1998
Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Adipose Tissue; Arterioles; Cell Survival; Cholesterol; Drug Combinations; Endothelial Cells; Endothelium, Vascular; Gangliosides; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Nanoparticles; NF-E2-Related Factor 2; Nitric Oxide; Nitric Oxide Synthase Type III; Papaverine; Peroxynitrous Acid; Phosphatidylcholines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Superoxides; Transfection; Vascular Diseases; Vasodilator Agents

2016
PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction.
    Journal of liposome research, 2018, Volume: 28, Issue:2

    Topics: Acetylcholine; Amyloidogenic Proteins; Amyloidosis; Arterioles; Cholesterol; Clusterin; Endothelial Cells; Endothelium, Vascular; Humans; Liposomes; Nanoparticles; Papaverine; Particle Size; Phosphatidylcholines; Polyethylene Glycols; Vasodilation

2018